AFT Pharma's Pipeline Fuels Growth
AFT Pharmaceuticals Unveils Multi-Billion-Dollar Pipeline, Targets Strong Revenue Growth and Global Expansion
Anonymous
Key Points
1
AFT has a collaboration with Stablepharma Plc to develop temperature-stabilised injectable drugs, highlighting a cost-efficient development pathway with a large potential global market.
2
Maxigesic IV has already generated tangible monetization for investors, including US$21 million in licensing income and US$5.5 million in royalties on sales, with additional multi-million-dollar benefits from ongoing activities.
3
Pascomer, a treatment for Facial Port Wine Stains, is currently in a Phase II dose-ranging study and targets a global market potential exceeding US$1 billion.
4
AFT’s medicines are now available in 87 countries with distribution agreements spanning more than 100, complemented by direct operations in Australia, New Zealand, and the UK as part of its broad global footprint.
5
The company noted a tentative FDA approval this month for a room-temperature stable cream for Facial Angiofibromas associated with Tuberous Sclerosis Complex, described as the third FDA approval for a patented medicine it developed.
AFT Pharmaceuticals has unveiled a sweeping R&D pipeline targeting multi-billion-dollar global markets, as the company reported NZ$254.7 million in revenue for FY26 — a 22% jump — and guided FY27 sales above NZ$300 million, according to Kalkine. The New Zealand-based drugmaker, which has grown revenue at a 17.6% compound annual rate since FY05, now sells medicines in 87 countries and holds direct operations in Australia, New Zealand, and the UK.
At its FY26 Investor Day, AFT detailed eight patented projects, 24 off-patent injectables, and a roster of early-stage assets, all designed to sustain its two-decade growth run, Finn News Network reported. CEO and founder Hartley Atkinson said the company's self-funding commercial model underpins continued pipeline investment without needing outside capital.
Four Flagship Programs Each Chase Billion-Dollar Markets
AFT's headline asset is an improved intravenous iron therapy targeting a US$7.4 billion market, according to Kalkine. Current iron infusions carry safety drawbacks, and AFT's version is designed to fix them. The company also spotlighted Pascomer, a cream for Facial Port Wine Stains now in a Phase II dose-ranging study, with a global market potential exceeding US$1 billion.
A third program targets infantile haemangiomas — abnormal clusters of blood vessels in newborns — while a fourth uses a technology that lets IV medicines stay stable at room temperature. The Market Online reported that each of these four projects addresses a market worth more than US$1 billion, though some timelines depend on development success.
Maxigesic IV Already Delivering Real Cash to Investors
AFT's pain drug Maxigesic IV is no longer just a pipeline promise. The product has already generated US$21 million in licensing income and US$5.5 million in royalties on sales, according to Kalkine. Those numbers give investors a concrete taste of what monetization looks like as other pipeline drugs mature.
CEO Atkinson told The Market Online that the company's global reach — now spanning distribution agreements in more than 100 countries — gives each new drug a ready-made commercial runway. That scale means AFT can launch a new product without building new infrastructure from scratch.
Third FDA Approval Arrives for Room-Temperature Stable Cream
AFT received a tentative FDA approval this month for a cream treating Facial Angiofibromas — small benign tumours linked to a rare genetic condition called Tuberous Sclerosis Complex. Kalkine described it as AFT's third FDA approval for a patented medicine it developed in-house. The cream is notable because it stays stable at room temperature, removing cold-chain storage costs.
That same room-temperature storage technology sits at the heart of AFT's collaboration with Stablepharma Plc, a partnership designed to develop a broad range of temperature-stable injectable drugs, Finn News Network reported. AFT says the partnership offers a cost-efficient path to a large global injectable market.
Self-Funding Model Powers Continued Global Expansion
AFT's growth has been built on a simple idea: use profits from selling medicines to fund new drug development. The company's NZ$33 million initial public offering has grown into a business now guiding above NZ$300 million in FY27 revenue with higher operating profit, according to Kalkine. That trajectory spans a 17.6% compound annual growth rate over two decades.
Atkinson told The Market Online that direct operations in Australia, New Zealand, and the UK anchor the business, while partnerships handle the remaining 84-plus countries. He said the dual model keeps costs lean while giving AFT the footprint to sell any new drug it develops at meaningful global scale.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
11
Articles
2
Reach
13
Topics
A
AnonymousAuthor
